- Home
- NLSP vs ADTX Comparison
NLSP vs ADTX Comparison
Compare NLSP & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- ADTX
- Stock Information
- Founded
- NLSP 2015
- ADTX 2017
- Country
- NLSP Switzerland
- ADTX United States
- Employees
- NLSP N/A
- ADTX N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- ADTX Health Care
- Exchange
- NLSP Nasdaq
- ADTX Nasdaq
- Market Cap
- NLSP 5.8M
- ADTX 5.3M
- IPO Year
- NLSP 2021
- ADTX 2020
- Fundamental
- Price
- NLSP $2.30
- ADTX $1.54
- Analyst Decision
- NLSP
- ADTX
- Analyst Count
- NLSP 0
- ADTX 0
- Target Price
- NLSP N/A
- ADTX N/A
- AVG Volume (30 Days)
- NLSP 423.9K
- ADTX 109.4K
- Earning Date
- NLSP 06-17-2025
- ADTX 05-15-2025
- Dividend Yield
- NLSP N/A
- ADTX N/A
- EPS Growth
- NLSP N/A
- ADTX N/A
- EPS
- NLSP N/A
- ADTX N/A
- Revenue
- NLSP N/A
- ADTX $55,323.00
- Revenue This Year
- NLSP N/A
- ADTX $15,768.94
- Revenue Next Year
- NLSP N/A
- ADTX N/A
- P/E Ratio
- NLSP N/A
- ADTX N/A
- Revenue Growth
- NLSP N/A
- ADTX N/A
- 52 Week Low
- NLSP $1.30
- ADTX $1.34
- 52 Week High
- NLSP $18.39
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- NLSP 65.15
- ADTX 35.55
- Support Level
- NLSP $1.58
- ADTX $1.42
- Resistance Level
- NLSP $2.39
- ADTX $1.63
- Average True Range (ATR)
- NLSP 0.23
- ADTX 0.13
- MACD
- NLSP 0.02
- ADTX 0.13
- Stochastic Oscillator
- NLSP 89.29
- ADTX 40.82
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.